EGFR Gene Variants Are Associated with Specific Somatic Aberrations in Glioma

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Wibom, Carl ^a   Ghasimi, Soma ^a   Van Loo, Peter ^b,e   Brännström, Thomas ^a   Trygg, Johan ^a   Lau, Ching ^c   Henriksson, Roger ^d   Bergenheim, Tommy ^a   Andersson, Ulrika ^a   Rydén, Patrik ^a   Melin, Beatrice ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; FEMALE; GENE; GENE DELETION; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; GENOTYPING TECHNIQUE; GLIOBLASTOMA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; BRAIN NEOPLASMS; DNA COPY NUMBER VARIATIONS; FEMALE; GENE AMPLIFICATION; GENOTYPE; GLIOMA; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84870926183     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047929     Document Type: Article

References (22)

1. Sanson M, Hosking FJ, Shete S, Zelenika D, Dobbins SE, et al. (2011) Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet 20: 2897-2904.
2. Shete S, Hosking FJ, Robertson LB, Dobbins SE, Sanson M, et al. (2009) Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 41: 899-904.
3. Wrensch M, Jenkins RB, Chang JS, Yeh RF, Xiao Y, et al. (2009) Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 41: 905-908.
4. Andersson U, Schwartzbaum J, Wiklund F, Sjostrom S, Liu Y, et al. (2010) A comprehensive study of the association between the EGFR and ERBB2 genes and glioma risk. Acta Oncol 49: 767-775.
5. Schwartzbaum JA, Xiao Y, Liu Y, Tsavachidis S, Berger MS, et al. (2010) Inherited variation in immune genes and pathways and glioblastoma risk. Carcinogenesis 31: 1770-1777.
6. TCGA TCGATRN (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
7. Melin B, (2011) Genetic causes of glioma: new leads in the labyrinth. Curr Opin Oncol 23: 643-647.
8. Barber LJ, Youds JL, Ward JD, McIlwraith MJ, O'Neil NJ, et al. (2008) RTEL1 maintains genomic stability by suppressing homologous recombination. Cell 135: 261-271.
9. Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, et al. (2003) hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene 22: 131-146.
10. Saavedra HI, Fukasawa K, Conn CW, Stambrook PJ, (1999) MAPK mediates RAS-induced chromosome instability. J Biol Chem 274: 38083-38090.
11. Cymer F, Schneider D, (2010) Transmembrane helix-helix interactions involved in ErbB receptor signaling. Cell Adh Migr 4: 299-312.
12. Jenkins RB, Wrensch MR, Johnson D, Fridley BL, Decker PA, et al. (2011) Distinct germ line polymorphisms underlie glioma morphologic heterogeneity. Cancer Genet 204: 13-18.
13. Simon M, Hosking FJ, Marie Y, Gousias K, Boisselier B, et al. (2010) Genetic risk profiles identify different molecular etiologies for glioma. Clin Cancer Res 16: 5252-5259.
14. Diskin SJ, Li M, Hou C, Yang S, Glessner J, et al. (2008) Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res 36: e126.
15. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, et al. (2010) Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 107: 16910-16915.
16. Lystig TC, (2003) Adjusted P values for genome-wide scans. Genetics 164: 1683-1687.
17. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251.
18. Ekstrand AJ, Longo N, Hamid ML, Olson JJ, Liu L, et al. (1994) Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 9: 2313-2320.
19. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, et al. (1996) Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 6: 217-223; discussion 223-214.
20. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M, (2005) Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res 11: 1119-1128.
21. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
22. Feng J, Kim ST, Liu W, Kim JW, Zhang Z, et al. (2012) An integrated analysis of germline and somatic, genetic and epigenetic alterations at 9p21.3 in glioblastoma. Cancer 118: 232-240.